Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus LAROTID.
BACTOCILL vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic